The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease
Open accessAbstract
BACKGROUND: Acute exacerbations of chronic obstructive pulmonary disease (COPD) are a major cause of hospital admission and mortality. They contribute to long-term decline in lung function, physical capacity and quality of life. The most common causes are infective, and treatment includes antibiotics, bronchodilators and systemic corticosteroids as anti-inflammatory agents. OBJECTIVES: To assess the effects of corticosteroids administered orally or parenterally for treatment of acute exacerbations of COPD, and to compare the efficacy of parenteral versus oral administration. SEARCH METHODS: We carried out searches using the Cochrane Airways Group Specialised Register of Trials, MEDLINE and CENTRAL (Cochrane Central Register of Controlled Trials), and checked references of included studies and trials registries. We conducted the last search in May 2014. SELECTION CRITERIA: Randomised controlled trials comparing corticosteroids administered orally or parenterally with an appropriate placebo, or comparing oral corticosteroids with parenteral corticosteroids in the treatment of people with acute exacerbations of COPD. Other interventions (e.g. bronchodilators and antibiotics) were standardised for both groups. We excluded clinical studies of acute asthma. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by The Cochrane Collaboration. MAIN RESULTS: Sixteen studies (n = 1787) met inclusion criteria for the comparison systemic corticosteroid versus placebo and 13 studies contributed data (n = 1620). Four studies (n = 298) met inclusion criteria for the comparison oral corticosteroid versus parenteral corticosteroid and three studies contributed data (n = 239). The mean age of participants with COPD was 68 years, median proportion of males 82% and mean forced expiratory volume in one second (FEV1) per cent predicted at study admission was 40% (6 studies; n = 633). We judged risk of selection, detection, attrition and reporting bias as low or unclear in all studies. We judged risk of performance bias high in one study comparing systemic corticosteroid with control and in two studies comparing intravenous corticosteroid versus oral corticosteroid.Systemic corticosteroids reduced the risk of treatment failure by over half compared with placebo in nine studies (n = 917) with median treatment duration 14 days, odds ratio (OR) 0.48 (95% confidence interval (CI) 0.35 to 0.67). The evidence was graded as high quality and it would have been necessary to treat nine people (95% CI 7 to 14) with systemic corticosteroids to avoid one treatment failure. There was moderate-quality evidence for a lower rate of relapse by one month for treatment with systemic corticosteroid in two studies (n = 415) (hazard ratio (HR) 0.78; 95% CI 0.63 to 0.97). Mortality up to 30 days was not reduced by treatment with systemic corticosteroid compared with control in 12 studies (n = 1319; OR 1.00; 95% CI 0.60 to 1.66).FEV1, measured up to 72 hours, showed significant treatment benefits (7 studies; n = 649; mean difference (MD) 140 mL; 95% CI 90 to 200); however, this benefit was not observed at later time points. The likelihood of adverse events increased with corticosteroid treatment (OR 2.33; 95% CI 1.59 to 3.43). Overall, one extra adverse effect occurred for every six people treated (95% CI 4 to 10). The risk of hyperglycaemia was significantly increased (OR 2.79; 95% CI 1.86 to 4.19). For general inpatient treatment, duration of hospitalisation was significantly shorter with corticosteroid treatment (MD -1.22 days; 95% CI -2.26 to -0.18), with no difference in length of stay the intensive care unit (ICU) setting.Comparison of parenteral versus oral treatment showed no significant difference in the primary outcomes of treatment failure, relapse or mortality or for any secondary outcomes. There was a significantly increased rate of hyperglycaemia in one study (OR 4.89; 95% CI 1.20 to 19.94). AUTHORS' CONCLUSIONS: There is high-quality evidence to support treatment of exacerbations of COPD with systemic corticosteroid by the oral or parenteral route in reducing the likelihood of treatment failure and relapse by one month, shortening length of stay in hospital inpatients not requiring assisted ventilation in ICU and giving earlier improvement in lung function and symptoms. There is no evidence of benefit for parenteral treatment compared with oral treatment with corticosteroid on treatment failure, relapse or mortality. There is an increase in adverse drug effects with corticosteroid treatment, which is greater with parenteral administration compared with oral treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07492-2 · Cited by 7,007
PAUWELS, R. A., BUIST, A. S., CALVERLEY, P. M. A., JENKINS, C. R., & HURD, S. S. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.5.2101039 · Cited by 6,587
Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
Hurst, J. R., Vestbo, J., Anzueto, A., Locantore, N., Müllerova, H., Tal-Singer, R., Miller, B., Lomas, D. A., Agusti, A., MacNee, W., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909883 · Cited by 2,981
Antibiotic Therapy in Exacerbations of Chronic Obstructive Pulmonary Disease
ANTHONISEN, N. R., MANFREDA, J., WARREN, C. P. W., HERSHFIELD, E. S., HARDING, G. K. M., & NELSON, N. A. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-2-196 · Cited by 2,492
Buist, A. S., McBurnie, M. A., Vollmer, W. M., Gillespie, S., Burney, P., Mannino, D. M., Menezes, A. M., Sullivan, S. D., Lee, T. A., Weiss, K. B., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61377-4 · Cited by 2,366
Effect of Exacerbation on Quality of Life in Patients with Chronic Obstructive Pulmonary Disease
SEEMUNGAL, T. A. R., DONALDSON, G. C., PAUL, E. A., BESTALL, J. C., JEFFRIES, D. J., & WEDZICHA, J. A. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.5.9709032 · Cited by 2,312
Donaldson, G. C. (2002) · Thorax · doi:10.1136/thorax.57.10.847 · Cited by 2,272
Cited by
Chronic obstructive pulmonary disease
Decramer, M., Janssens, W., & Miravitlles, M. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60968-9 · Cited by 972
Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission
Stolz, D., Mkorombindo, T., Schumann, D. M., Agusti, A., Ash, S. Y., Bafadhel, M., Bai, C., Chalmers, J. D., Criner, G. J., Dharmage, S. C., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01273-9 · Cited by 681
Bafadhel, M., McKenna, S., Terry, S., Mistry, V., Pancholi, M., Venge, P., Lomas, D. A., Barer, M. R., Johnston, S. L., Pavord, I. D., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201108-1553oc · Cited by 612
Baker, E. H. (2006) · Thorax · doi:10.1136/thx.2005.051029 · Cited by 418
Mallia, P., Message, S. D., Gielen, V., Contoli, M., Gray, K., Kebadze, T., Aniscenko, J., Laza-Stanca, V., Edwards, M. R., Slater, L., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0833oc · Cited by 415
Metadata
- Authors
- Walters, J. A., Gibson, P. G., Wood-Baker, R., Hannay, M., & Walters, E. H.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2009-01-21
- Volume
- 2009
- Issue
- 1
- Pages
- CD001288-CD001288
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W2111618125
- Cited by
- 279
- References
- 60
- Type
- reference entry
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. https://app.cochat.ai/papers/10.1002/14651858.cd001288.pub3
- The paper
- Walters, J. A., Gibson, P. G., Wood-Baker, R., Hannay, M., & Walters, E. H. (2009). Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd001288.pub3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.